Recap: CancerNetwork® Tweet Chat on Prostate Cancer

Article

In a mock tumor board on prostate cancer on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review.

In a mock tumor board on prostate cancer organized by CancerNetwork® on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review, with guest commentary on each case offered from experts in the field.

Led by Judd W. Moul, MD, FACS, a urologic oncologist at Duke Cancer Center and Duke Urology Clinic, the chat featured guest commentary from Daniel Spratt, MD, chief of the Genitourinary Radiotherapy Program, associate chair of Clinical Research, and the Laurie Snow Endowed Research Professor at the Rogel Cancer Center of the University of Michigan, Alicia K. Morgans, MD, MPH, associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine, and Stacy Loeb, MD, MSc, PhD (hon.), professor of Urology and Population Health at NYU Langone Health and the Manhattan Veterans Affairs.

In case you missed it, here is a recap of the questions presented and the answers selected by participants:

tweet chat question 1

tweet chat question 2

tweet chat question 3

tweet chat question 4

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content